[
  {
    "ts": null,
    "headline": "S&P 500 Gains and Losses Today: International Paper Stock Pops on Upbeat Growth Outlook",
    "summary": "The S&P 500 edged 0.2% higher on Tuesday, March 25, despite a report showing that consumer confidence fell to its lowest point in more than a decade.",
    "url": "https://finnhub.io/api/news?id=9601d2f1daded87bbc44d3c2cfc0e5f2843a28893eda33c9941f040b61f150b9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742937077,
      "headline": "S&P 500 Gains and Losses Today: International Paper Stock Pops on Upbeat Growth Outlook",
      "id": 133444859,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The S&P 500 edged 0.2% higher on Tuesday, March 25, despite a report showing that consumer confidence fell to its lowest point in more than a decade.",
      "url": "https://finnhub.io/api/news?id=9601d2f1daded87bbc44d3c2cfc0e5f2843a28893eda33c9941f040b61f150b9"
    }
  },
  {
    "ts": null,
    "headline": "These Dividend Aristocrats’ Stocks Can Protect You From the Market Selloff",
    "summary": "If markets remain rocky, either because of the Trump administration’s trade war or soft economic data, the aristocrats could continue to outperform.  “Our favorite defensive dividend strategy, dividend aristocrats, is a good place for investors to ‘hide’ in the event of an economic slowdown or recessionary environment,” he wrote.  The easiest way for investors to bet on long-time dividend payers is through an exchange-traded fund such as the  often known by its ticker, NOBL.",
    "url": "https://finnhub.io/api/news?id=3aed38b1cc6e220c5c199dba3034c4b89a07493ce37d153c21b89886887387f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742922780,
      "headline": "These Dividend Aristocrats’ Stocks Can Protect You From the Market Selloff",
      "id": 133444860,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "If markets remain rocky, either because of the Trump administration’s trade war or soft economic data, the aristocrats could continue to outperform.  “Our favorite defensive dividend strategy, dividend aristocrats, is a good place for investors to ‘hide’ in the event of an economic slowdown or recessionary environment,” he wrote.  The easiest way for investors to bet on long-time dividend payers is through an exchange-traded fund such as the  often known by its ticker, NOBL.",
      "url": "https://finnhub.io/api/news?id=3aed38b1cc6e220c5c199dba3034c4b89a07493ce37d153c21b89886887387f2"
    }
  },
  {
    "ts": null,
    "headline": "S&P 500 struggles to extend its relief rally. Here are the stocks capping market upside.",
    "summary": "S&P 500 struggles to extend its relief rally. Here are the stocks capping market upside.",
    "url": "https://finnhub.io/api/news?id=d26e7f58a653e3fd29bc58e94abb039bec22520071ab0039419d4d6a620439f6",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742912096,
      "headline": "S&P 500 struggles to extend its relief rally. Here are the stocks capping market upside.",
      "id": 133448536,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "S&P 500 struggles to extend its relief rally. Here are the stocks capping market upside.",
      "url": "https://finnhub.io/api/news?id=d26e7f58a653e3fd29bc58e94abb039bec22520071ab0039419d4d6a620439f6"
    }
  },
  {
    "ts": null,
    "headline": "3 Healthcare Stocks in the Doghouse",
    "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 5.9%. This performance was discouraging since the S&P 500 held steady.",
    "url": "https://finnhub.io/api/news?id=b50a9ac859f2b1cd30a9f79672d9affdf2f3f3eab64743b675fad70a93198319",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742907701,
      "headline": "3 Healthcare Stocks in the Doghouse",
      "id": 133377698,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 5.9%. This performance was discouraging since the S&P 500 held steady.",
      "url": "https://finnhub.io/api/news?id=b50a9ac859f2b1cd30a9f79672d9affdf2f3f3eab64743b675fad70a93198319"
    }
  },
  {
    "ts": null,
    "headline": "5 Large Drug Stocks to Watch as Industry Recovers",
    "summary": "R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novo Nordisk (NVO), Novartis (NVS), Pfizer (PFE) and Bayer (BAYRY) are worth retaining in one's portfolio",
    "url": "https://finnhub.io/api/news?id=7fffeeb199277a0e155cbb1cbd8dbf331de057e4d45b415e7f5a98fa48cb34b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742899620,
      "headline": "5 Large Drug Stocks to Watch as Industry Recovers",
      "id": 133375596,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novo Nordisk (NVO), Novartis (NVS), Pfizer (PFE) and Bayer (BAYRY) are worth retaining in one's portfolio",
      "url": "https://finnhub.io/api/news?id=7fffeeb199277a0e155cbb1cbd8dbf331de057e4d45b415e7f5a98fa48cb34b7"
    }
  }
]